Event Information
October Breakfast Meeting:
Join BIOCOM for a fireside chat with Greg Lucier, Chairman & Chief Executive Officer of Life Technologies Corporation, and Wain Fishburn, Partner at Cooley LLP, on the future of personalized genomic medicine. Our discussion will address industry challenges, opportunities to fill new gaps, whether instrument or service driven approaches will drive the business model and how international competition may play a role in the industry. We will also cover how our region is positioned as a nexus for activity in this arena.
Speakers:
Gregory T. Lucier
Chairman and Chief Executive Officer, Life Technologies
Gregory T. Lucier serves as Chief Executive Officer of Life Technologies and as Chairman of the Company’s Board of Directors. Previously, he served as Chairman and Chief Executive Officer of Invitrogen Corporation, which merged with Applied Biosystems in November 2008 to form Life Technologies. The Company is one of the largest providers of systems, biological reagents, and services, supplying scientists around the world in every way that life science technologies are applied. The company aims to improve the human condition by enabling basic research, accelerating drug discovery and development, andadvancing scientific exploration in areas such as regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Mr. Lucier has leveraged his background in healthcare management to prepare the company to participate in and shape the new era of personalized medicine. Mr. Lucier serves on the Board of Directors at Synthetic Genomics, Inc. and Carefusion Corporation, and serves as Chairman of the Board of Trustees of the Sanford Burnham Medical Research Institute. He received his B.S. in Engineering from Pennsylvania State University and an M.B.A. from Harvard Business School.
M. Wainright Fishburn, Jr.
Partner, Cooley LLP
Wain Fishburn is a founding partner of Cooley LLP’s San Diego office and represents high growth technology and life sciences corporations ranging from start-up to public. Mr. Fishburn is an active community leader and has shaped many industry organizations. He is a founding board member of the Corporate Directors Forum, as well as BIOCOM, where he currently serves as Vice Chair of the BIOCOM Board of Directors. He is a member of the Board of Trustees and the Executive Committee of the Sanford-Burnham Institute for Medical Research. He serves on the Board of Directors for the Critical Path Institute, an independent institute created in part by the FDA, dedicated toimproving the regulatory path for innovative medical therapies. Mr. Fishburn is a founder of two public companies and prior to law school, worked in the corporate environment assisting with the divestiture of a group of 12 operating companies. He received his J.D. degree from the University of California, Hastings College of the Law, and has served as President of the Hastings Board of Governors.
| When | Tuesday, October 26, 2010 7:00 a.m. - 9:00 a.m. |
 Add to Calendar |
| RSVP | Monday, October 25, 2010 12:00 p.m. |
| Where |
Hyatt Regency La Jolla 3777 La Jolla Village Drive San Diego, California 92122 |
 Get Driving Directions |
| Planner | |